Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

NIH

Sponsor class

Conditions

Sjogren's Syndrome

Interventions

DRUG: tofacitinib
OTHER: Placebo

Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)